Abstract
The use of chymopapain in chemonucleolysis of the herniated disc responsible for sciatica, began in July 1963 when Lyman Smith injected the first human subject. The procedure was utilized in more than 16000 patients until 1975 when, because of the equivocal results of a double-blind study, the FDA stopped the investigation in the USA. The investigation was not resumed until Scott Smith and Lyman Smith founded a company and produced a new product in 1979.
Preview
Unable to display preview. Download preview PDF.
References
Javid MJ and Coll(1983) Safety and efficacy of Chymopapain (Chymodiactin) in herniated nucleus pulposus with sciatica. JAMA, May 13, Vol 249, n° 18, pp 2489–2494
Norbry EJ (1985) United States experience with chemonucleolysis. Current concepts in chemonu- cleolysis, by J. Carl Sutton, ed., Royal Society of Medicine, International congress and symposium series, published by the Royal Society of Medicine, pp 109–119
McDermott D (1985) Post-marketing surveillance review. Current concepts in chemonucleolysis, J. Carl Sutton, ed., Royal Society of Medicine, International congress and symposium series 72, published by the Royal Society of Medicine, pp 98–104
Cochayne and Coll (1985) Relative activity and stability of commercially available chymopapain formulations for chemonucleolysis. Current concepts in chemonucleolysis, J.Carl Sutton, ed. Royal Society of Medicine, International congress and symposium series 72, published by the Royal Society of Medicine, pp 9–16
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Caulin, F. (1986). Chymodiactin. In: Bonneville, JF. (eds) Focus on Chemonucleolysis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71182-4_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-71182-4_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71184-8
Online ISBN: 978-3-642-71182-4
eBook Packages: Springer Book Archive